A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which examined the long-term effects of CAR-T cell therapy, characterized one of the first patients treated as part of clinical trials in 2010 as “cured,” a term rarely used in oncology. CAR-T is a form of gene modified cell therapy involving permanently altering a patient’s T-cells to recognize, target and kill cancer cells, with the goal of eliciting an enduring immune response over the long-term.
